[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 16, 1998

Montelukast for Children With Asthma

Author Affiliations
 

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;280(11):967. doi:10-1001/pubs.JAMA-ISSN-0098-7484-280-11-jbk0916

To the Editor.—Montelukast (MK-0476) is an orally administered, specific cysteinyl leukotriene receptor antagonist now with labeling approved by the Food and Drug Administration for the treatment of asthma. The study by Dr Knorr and colleagues1 reported that montelukast improved morning forced expiratory volume in 1 second in 6- to 14-year-old children with chronic asthma. The most common adverse experiences were headache, asthma, and upper respiratory tract infection. However, the authors also reported an increase in fever (7.5% with montelukast vs 3.7% with placebo) and influenza (8.5% with montelukast vs 4.4% with placebo) and a decrease in abdominal pain (5% with montelukast vs 10.4% with placebo).

First Page Preview View Large
First page PDF preview
First page PDF preview
×